Summit Therapeutics Inc Ordinary Shares SMMT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Ivonescimab Plus Chemotherapy Shows Consistent, Favorable Overall Survival Results in Western and Asian Patients in Updated Analysis from Global Phase III HARMONi Study
-
Summit Therapeutics to Host Second Quarter 2026 Financial Results & Operational Progress Call on July 23, 2026
-
Summit Therapeutics Signs Agreement to Sell Phase III Asset Ridinilazole to Biossil, Inc.
-
Summit Therapeutics Announces Proposed Public Offering of Common Stock
-
Summit Therapeutics to Participate in the 47th Annual Goldman Sachs Global Healthcare Conference
-
An experimental lung-cancer drug could replace Keytruda one day. But investors aren't wowed.
-
Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China
-
Encouraging Global Phase II Ivonescimab Data in First-Line Metastatic Colorectal Cancer Presented at ASCO 2026
Trading Information
- Previous Close Price
- $14.63
- Day Range
- $14.66–15.70
- 52-Week Range
- $12.56–30.87
- Bid/Ask
- $14.65 / $14.67
- Shares Outstanding
- 776.16M
- Market Cap
- $11.48B
- Volume/Avg
- 3M / 5M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 265
- Website
- https://www.smmttx.com
Valuation
|
Metric
|
SMMT
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 20.80 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
SMMT
Financial Strength
|
Metric
|
SMMT
|
|---|---|
Quick Ratio | 7.19 |
Current Ratio | 7.41 |
Interest Coverage | — |
Quick Ratio
SMMT
Profitability
|
Metric
|
SMMT
|
|---|---|
Return on Assets (Normalized) | −86.94% |
Return on Equity (Normalized) | −102.92% |
Return on Invested Capital (Normalized) | −100.00% |
Return on Assets
SMMT
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|>W#Rft | LOCK|yvHZ | $122B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|F?N%$#t | LOCK|zPqf | $71B | |||
| argenx SE ADR
ARGX
| LOCK|r>WY@l | LOCK|?c& | $54B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|yM!pw? | LOCK|R?^ | $37B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|&Ms^YzW | LOCK|lW^KX | $36B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|fp<?<w>q | LOCK|L<LKr | $26B | |||
| Moderna Inc
MRNA
| LOCK|Qm^X#@ | LOCK|M!> | $24B | |||
| Incyte Corp
INCY
| LOCK|SLh#t# | LOCK|RMB | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|Y?K>mD | LOCK|TN% | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|<wTkvGr | LOCK|v& | $16B |
United States